Axsome Therapeutics, Inc.

NasdaqGM:AXSM Stock Report

Market Cap: US$5.3b

Axsome Therapeutics Management

Management criteria checks 3/4

Axsome Therapeutics' CEO is Herriot Tabuteau, appointed in Jan 2012, has a tenure of 13.33 years. total yearly compensation is $10.36M, comprised of 7.5% salary and 92.5% bonuses, including company stock and options. directly owns 0.015% of the company’s shares, worth $778.88K. The average tenure of the management team and the board of directors is 7 years and 10.4 years respectively.

Key information

Herriot Tabuteau

Chief executive officer

US$10.4m

Total compensation

CEO salary percentage7.5%
CEO tenure13.3yrs
CEO ownership0.01%
Management average tenure7yrs
Board average tenure10.4yrs

Recent management updates

Recent updates

Axsome Therapeutics Q1: Marketing-Driven Growth Masks Profitability Concerns

May 06
author-image

R&D Pipeline And NDAs Will Unlock New Approvals

Apr 28 Ongoing R&D and product launch efforts, including key NDA submissions, may significantly enhance future revenues through new product approvals.

Is Axsome Therapeutics (NASDAQ:AXSM) A Risky Investment?

Apr 15
Is Axsome Therapeutics (NASDAQ:AXSM) A Risky Investment?

Axsome Q4 Earnings: Revenues Rising, Skepticism Lingering

Feb 20

Axsome Settling Teva Patent Litigation Is Another Positive Catalyst -- Upgrade

Feb 11

After Leaping 59% Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Are Not Flying Under The Radar

Feb 11
After Leaping 59% Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Are Not Flying Under The Radar

Axsome Therapeutics Remains A Buy Despite AXS-05's Mixed Results

Dec 31

Investors Still Waiting For A Pull Back In Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Dec 23
Investors Still Waiting For A Pull Back In Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Axsome: Focus On AXS-12 Targeting Narcolepsy, Which Just Released Positive Data

Nov 29

Does Axsome Therapeutics (NASDAQ:AXSM) Have A Healthy Balance Sheet?

Nov 25
Does Axsome Therapeutics (NASDAQ:AXSM) Have A Healthy Balance Sheet?

Axsome Therapeutics Q3 Earnings: Stay For The Near Term Catalysts, Then Sell

Nov 12

Axsome: AXS-07 And Its Upcoming Second PDUFA

Oct 15

Getting In Cheap On Axsome Therapeutics, Inc. (NASDAQ:AXSM) Might Be Difficult

Sep 06
Getting In Cheap On Axsome Therapeutics, Inc. (NASDAQ:AXSM) Might Be Difficult

Axsome's Auvelity: High Hopes Meet Hefty Bills (Rating Downgrade)

Aug 06

Axsome Therapeutics: Lots Of Moving Parts

Jul 23

Health Check: How Prudently Does Axsome Therapeutics (NASDAQ:AXSM) Use Debt?

Jul 02
Health Check: How Prudently Does Axsome Therapeutics (NASDAQ:AXSM) Use Debt?

Why Axsome Therapeutics Is A Promising Stock Pick In CNS Treatments

May 10

Axsome: Unpacking Auvelity's First-Year Market Dynamics And Economic Challenges

Feb 21

Axsome Therapeutics: Clear Path Ahead For AXS07

Oct 05

Axsome to resubmit marketing application for migraine therapy in Q3 2023

Sep 29

Axsome: In The Middle Of Uncertainty Is Your Biggest Opportunity

Sep 16

Axsome begins enrolling in late-stage study of migraine drug AXS-07

Sep 01

Axsome gains 19% as FDA approves depression therapy

Aug 19

CEO Compensation Analysis

How has Herriot Tabuteau's remuneration changed compared to Axsome Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-US$278m

Dec 31 2024US$10mUS$780k

-US$287m

Sep 30 2024n/an/a

-US$311m

Jun 30 2024n/an/a

-US$309m

Mar 31 2024n/an/a

-US$296m

Dec 31 2023US$10mUS$750k

-US$239m

Sep 30 2023n/an/a

-US$202m

Jun 30 2023n/an/a

-US$184m

Mar 31 2023n/an/a

-US$159m

Dec 31 2022US$8mUS$685k

-US$187m

Sep 30 2022n/an/a

-US$160m

Jun 30 2022n/an/a

-US$150m

Mar 31 2022n/an/a

-US$141m

Dec 31 2021US$8mUS$685k

-US$130m

Sep 30 2021n/an/a

-US$126m

Jun 30 2021n/an/a

-US$114m

Mar 31 2021n/an/a

-US$100m

Dec 31 2020US$7mUS$575k

-US$103m

Sep 30 2020n/an/a

-US$99m

Jun 30 2020n/an/a

-US$95m

Mar 31 2020n/an/a

-US$90m

Dec 31 2019US$5mUS$435k

-US$68m

Sep 30 2019n/an/a

-US$53m

Jun 30 2019n/an/a

-US$42m

Mar 31 2019n/an/a

-US$37m

Dec 31 2018US$1mUS$435k

-US$31m

Compensation vs Market: Herriot's total compensation ($USD10.36M) is about average for companies of similar size in the US market ($USD8.78M).

Compensation vs Earnings: Herriot's compensation has increased whilst the company is unprofitable.

CEO

Herriot Tabuteau (56 yo)

13.3yrs

Tenure

US$10,364,688

Compensation

Dr. Herriot Tabuteau, MD founded Axsome Therapeutics, Inc. in January 2012 and has been its Chief Executive Officer, President and Chairman since January 2012. Dr. Tabuteau served as Interim Principal Fina...

Leadership Team

NamePositionTenureCompensationOwnership
Herriot Tabuteau
Founder13.3yrsUS$10.36m0.015%
$ 778.9k
Nick Pizzie
Chief Financial Officer7yrsUS$3.76m0.087%
$ 4.6m
Mark Jacobson
Chief Operating Officer9.6yrsUS$4.25m0.012%
$ 623.4k
Hunter Murdock
General Counsel & Secretary3.4yrsUS$3.25m0%
$ 0
Ari Maizel
Chief Commercial Officer1.6yrsUS$3.20m0%
$ 0

7.0yrs

Average Tenure

45yo

Average Age

Experienced Management: AXSM's management team is seasoned and experienced (7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Herriot Tabuteau
Founder13.3yrsUS$10.36m0.015%
$ 778.9k
Roger Jeffs
Independent Director10.4yrsUS$403.73k0.34%
$ 18.1m
Mark Saad
Independent Director10.4yrsUS$408.59k0.021%
$ 1.1m
Susan Mahony
Independent Director1.6yrsUS$398.31k0%
$ 0
Mark Coleman
Independent Lead Director10.4yrsUS$432.79k0.94%
$ 49.7m

10.4yrs

Average Tenure

56yo

Average Age

Experienced Board: AXSM's board of directors are seasoned and experienced ( 10.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/11 01:19
End of Day Share Price 2025/05/09 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Axsome Therapeutics, Inc. is covered by 25 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joel BeattyBaird
Esther Lannie HongBerenberg
Jason Matthew GerberryBofA Global Research